K T Rama Rao unveils BE's 300 Crore plant at Hyderabad

▴ K T Rama Rao unveils BEs 300 Crore plant at Hyderabad
Hyderabad based pharmaceutical co. Biological E Ltd.recently launched its new plant of Rs.300 crores at Genome Valley. This initiative will enhance the production and manufacture of new vaccines.

Pharmaceutical company Biological E. Limited on 17.02.2020 launched its new plant, built with an investment of Rs. 300 crore at Genome Valley here.Telangana's Industry Minister K.T. Rama Rao inaugurated the facility, which will generate employment for about 1,000 people.

Mahima Datla, Managing Director, Biological E. Limited, this new facility will help their existing vaccines plant enhance the production and manufacture new products, which are in the pipeline.The plant has come up on 29 acres in the Special Economic Zone at Genome Valley in Kolthur village on the outskirts of Hyderabad.

Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, Professor Baron Peter Piot, Director, London School of Hygiene and Tropical Medicine were also present.

Rao said the government was committed to make Telangana number one state in terms of industrial growth and employment generation with a special focus on life sciences.Rama Rao also unveiled BE's Typhoid Conjugate Vaccine. Recently, BE received the authorisation from the health regulatory authorities of India to license and market TCV.

TCV is an injectable single-dose vaccine to be administered to children of the age of above 6 months as well as adults. The clinical studies conducted in India demonstrated that the safety and immunogenicity profiles of this vaccine are comparable to the other licensed and WHO Pre-qualified Typhoid conjugate vaccine, Biological E. said.

This vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Siena (Italy), which first developed the asset and transferred it to BE in 2013. Subsequent developmental work on the vaccine was done by BE, including manufacturing process optimization and scale up, pre-clinical studies and full clinical trials in India.

This vaccine will be manufactured in BE's GMP manufacturing facilities in Hyderabad, India and could be commercially available within 3 months, it added.

Story Source : IANS

Tags : #Ktramarao #Hyderabadbasedbiologicaleltd #Typhoidconjugatevaccine #Gskvaccineinstitute

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Surviving Against the Odds: Steven Spinale's Journey After an Ingrown Hair Turns DeadlyMarch 29, 2024
10 reasons why media research and Planning are essential in Healthcare marketingMarch 29, 2024
The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024